A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

Trial Profile

A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs MINT 1526A (Primary) ; Bevacizumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Genentech
  • Most Recent Events

    • 06 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 12 Sep 2013 Planned end date changed from 1 Nov 2013 to 1 Feb 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top